Literature DB >> 25034390

Severe acute kidney injury and multiple myeloma: evaluation of kidney and patient prognostic factors.

Luís Rodrigues1, Marta Neves2, Helena Sá3, Henrique Gomes4, Jorge Pratas5, Mário Campos6.   

Abstract

BACKGROUND: Patients with multiple myeloma (MM) manifesting acute kidney injury (AKI) and who later recover renal function and independence from renal replacement therapy (RRT) are considered to have a better outcome. The aim of this work was to study the factors associated with renal function recovery (independence of hemodialysis) and longer survival in these patients.
METHODS: A retrospective single center study including patients with a diagnosis of MM and severe AKI, defined as stage 3 of the Kidney Disease: Improving Global Outcomes (KDIGO) criteria: 3.0 times baseline increase in serum creatinine (sCr) or increase in sCr to ≥4.0mg/dL or initiation of RRT, was conducted. Data was registry-based and collected between January 2000 and December 2011. We examined demographic and laboratorial data, presenting clinical features, precipitating factors, need for RRT and chemotherapy. Death was considered the primary endpoint.
RESULTS: Lower serum β2-microglobulin was the only independent factor associated with recovery of renal function and independence of RRT (OR 0.95, 95% CI: 0.91-0.99, P=0.02). The median survival after AKI was 10.7±12.1months. The factors associated with longer survival were independence of RRT (HR 2.21; 95% CI: 1.08-4.49; P=0.02), lower CRP (HR 1.07; 95% CI: 1.03-1.12; P=0.001) and younger age (HR 1.03; 95% CI: 1.01-1.06; P=0.005).
CONCLUSIONS: Our study suggests that MM patients with lower serum β2-microglobulin have a higher likelihood of recovering renal function after severe AKI. Independence of RRT, lower CRP and younger age are associated with longer survival.
Copyright © 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute kidney injury; Hemodialysis; Multiple myeloma; Prognosis

Mesh:

Substances:

Year:  2014        PMID: 25034390     DOI: 10.1016/j.ejim.2014.06.023

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  5 in total

1.  Ulinastatin Alleviates Rhabdomyolysis-Induced Acute Kidney Injury by Suppressing Inflammation and Apoptosis via Inhibiting TLR4/NF-κB Signaling Pathway.

Authors:  Jinxiang Wang; Guowu Xu; Heng Jin; Yanfen Chai; Xinyue Yang; Ziquan Liu; Shike Hou; Haojun Fan
Journal:  Inflammation       Date:  2022-06-06       Impact factor: 4.657

2.  Risk factors for renal impairment in patients with hematological cancer receiving antineoplastic treatment.

Authors:  Priscila Nunes Costa Travassos; Paulo Goberlânio de Barros Silva; Milena Oliveira Freitas; Marcus Davis Machado Braga; Fernando Barroso Duarte; Jéssica Karen de Oliveira Maia; Helena Pitombeira; Jacqueline Holanda de Sousa; Ana Paula Negreiros Nunes Alves
Journal:  Support Care Cancer       Date:  2022-05-21       Impact factor: 3.359

Review 3.  Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.

Authors:  P Fabbrini; K Finkel; M Gallieni; G Capasso; M Cavo; A Santoro; S Pasquali
Journal:  J Nephrol       Date:  2016-10-18       Impact factor: 3.902

4.  Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014.

Authors:  M Laforet; N Jourde-Chiche; F Haddad; M Sallee; A M Stoppa; P Brunet; B Dussol; S Burtey; B Gondouin
Journal:  Blood Cancer J       Date:  2016-03-25       Impact factor: 11.037

5.  Critically ill cancer patient's resuscitation: a Belgian/French societies' consensus conference.

Authors:  Anne-Pascale Meert; Sebastian Wittnebel; Stéphane Holbrechts; Anne-Claire Toffart; Jean-Jacques Lafitte; Michael Piagnerelli; France Lemaitre; Olivier Peyrony; Laurent Calvel; Jean Lemaitre; Emmanuel Canet; Alexandre Demoule; Michael Darmon; Jean-Paul Sculier; Louis Voigt; Virginie Lemiale; Frédéric Pène; David Schnell; Etienne Lengline; Thierry Berghmans; Laurence Fiévet; Christiane Jungels; Xiaoxiao Wang; Ionela Bold; Aureliano Pistone; Adriano Salaroli; Bogdan Grigoriu; Dominique Benoit
Journal:  Intensive Care Med       Date:  2021-09-20       Impact factor: 17.440

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.